“Development of Nanocrystal Formulations With Improved Dissolution And Bioavailability for BCS Classs-II Drug- Quitapine”, Journal of Pharmaceutical Negative Results, pp. 5113–5120, Aug. 2022, doi: 10.47750/pnr.2022.13.S08.670.